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Gene transfer into autologous hematopoietic stem 
cells by γ-retroviral vectors (gRV) is an effective treat-
ment for adenosine deaminase (ADA)–deficient severe 
combined immunodeficiency (SCID). However, cur-
rent gRV have significant potential for insertional 
mutagenesis as reported in clinical trials for other 
primary immunodeficiencies. To improve the efficacy 
and safety of ADA-SCID gene therapy (GT), we gen-
erated a self-inactivating lentiviral vector (LV) with a 
codon-optimized human cADA gene under the control 
of the short form elongation factor-1α promoter (LV 
EFS ADA). In ADA−/− mice, LV EFS ADA displayed high-
efficiency gene transfer and sufficient ADA expression 
to rescue ADA−/− mice from their lethal phenotype with 
good thymic and peripheral T- and B-cell reconstitu-
tion. Human ADA-deficient CD34+ cells transduced 
with 1–5 × 107 TU/ml had 1–3 vector copies/cell and 
expressed 1–2x of normal endogenous levels of ADA, 
as assayed in vitro and by transplantation into immune-
deficient mice. Importantly, in vitro immortalization 
assays demonstrated that LV EFS ADA had significantly 
less transformation potential compared to gRV vectors, 
and vector integration-site analysis by nrLAM-PCR of 
transduced human cells grown in immune-deficient 
mice showed no evidence of clonal skewing. These 
data demonstrated that the LV EFS ADA vector can 
effectively transfer the human ADA cDNA and promote 
immune and metabolic recovery, while reducing the 
potential for vector-mediated insertional mutagenesis.
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publication 21 January 2014. doi:10.1038/mt.2013.265
INTRODUCTION
Adenosine deaminase–deficient severe combined immunode-
ficiency (ADA-SCID) is a severe primary immunodeficiency 
characterized by impaired T-, B-, and NK-cell development and 
accounts for 10–15% of all cases of SCID.1 ADA catalyzes the 
deamination of deoxyadenosine and adenosine to deoxyinosine 
and inosine respectively, and the lack of ADA leads to increased 
intracellular conversion of deoxyadenosine to deoxyadenosine 
triphosphate (dATP) thus expanding the dATP pool. High levels 
of dATP affect lymphocyte development, viability, and function 
causing the immune defects seen in this condition.2 Clinically, 
patients present with failure to thrive, recurrent and opportunistic 
infections and death in the first year of life if left untreated.3,4 A 
murine model recapitulates the human disease with similar meta-
bolic and immunological abnormalities and untreated mice die 
after 3 weeks from pulmonary insufficiency, which results from 
the metabolic consequences of the disease.5
Treatment options for ADA SCID are limited and the main-
stay of treatment is allogeneic hematopoietic stem cell transplant 
(HSCT) which offers good survival outcome when well-matched 
family donors are available. Survival following HSCT from 
matched unrelated donors (67%), mismatched unrelated donors 
(29%), or parental donors (43%) are less good.6 Enzyme replace-
ment therapy (ERT) with pegylated bovine ADA (PEG-ADA) 
results in effective metabolic detoxification, but long-term 
immune recovery is suboptimal and very poor in some cases.7 
Thus, there is a clear need for effective and sustained alternative 
treatment options.
ADA-SCID has long been held as a model disorder for gene 
therapy (GT) and was the first genetic disorder for which GT was 
attempted. Early trials of GT using γ-retroviral vectors (gRVs) 
targeting correction of peripheral blood (PB) lymphocytes or 
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autologous hematopoietic stem cells (HSCs) or a combination of 
the two showed limited success, and immune recovery could not 
be attributed to GT alone, since ERT was continued after the GT 
procedure.8 Subsequent trials also using gRVs but with the use 
of nonmyeloablative conditioning and withdrawal of ERT have 
shown improved outcomes with recovery of immune and meta-
bolic parameters.9,10 In the three studies so far undertaken, 31 
of 42 patients (73.8%) have remained off ERT following GT, but 
immune reconstitution remains suboptimal with T-cell numbers 
at the lower limit of the normal range and approximately half of 
the patients remaining on immunoglobulin replacement therapy 
due to incomplete B-cell reconstitution.11–13
More importantly, despite the absence of any adverse events in 
ADA-SCID patients, the ongoing use of gRVs has raised concerns. 
In clinical trials of gRV-mediated autologous HSC GT for SCID-X1, 
X-CGD, and Wiskott–Aldrich syndrome, there has been a high 
incidence of gRV-mediated insertional mutagenesis.14–19 Upon vec-
tor integration, the strong enhancer elements that reside in the long 
terminal repeat (LTR) promoter elements of gRVs can transactivate 
adjacent genes to initiate the transformation process. In ADA gRV 
studies, vector insertions near known oncogenes have also been 
reported, although there have been no clinical clonal outgrowths.20 
A number of regulatory agencies have recommended a move away 
from the continued use of gRVs and the development of safer vector 
designs. Self-inactivating (SIN) vectors, based on the HIV-1 lenti-
viral vector (LV), in which the HIV LTR is deleted and transgene 
expression placed under the control of an internal promoter with 
minimal or no enhancer activity have received considerable atten-
tion.21–23 The advantages of a SIN LV include the improved ability 
of LV to transduce long-term engrafting HSC which may allow 
improved immune recovery but also the significantly decreased 
potential for insertional mutagenesis, which has been demonstrated 
in a number of in vitro24,25 and in vivo studies.26,27
For these reasons, we investigated the use of a SIN LV the for 
treatment of ADA-SCID. Following in vitro comparative stud-
ies using LVs expressing human ADA under the transcriptional 
control of either the phosphoglycerate kinase promoter, the MND 
retroviral vector LTR, or the short form of the elongation factor 
1α promoter (EFS), the LV EFS ADA vector configuration was 
selected for further preclinical assessment in relevant models of 
ADA deficiency.28 We demonstrate that the LV EFS ADA is capable 
of effective and consistent ADA gene transfer and expression that 
is equivalent or greater than the currently used gRV, while having 
a significantly lower capacity for inducing clonal outgrowth. The 
results obtained from this study provide compelling evidence for 
the translation of this vector to clinical application.
RESULTS
LV EFS ADA can efficiently transduce murine and 
human HSC
We have previously cloned the LV EFS ADA vector with a third gen-
eration SIN LV design under the transcriptional control of the short 
version EFS promoter (Figure 1a,b).28 The transduction efficiency 
and transgene expression of the LV vector was confirmed in mul-
tiple cell lines in vitro (data not shown). We then compared trans-
duction efficiency and transgene expression of the LV EFS ADA 
with the gRVSFada/W vector used in a clinical trial for ADA-SCID 
GT in primary cells.13 Lineage depleted bone marrow cells (Lin-) 
isolated from ADA−/− mice (ADA−/− HSC) were isolated and trans-
duced with viral vectors at a multiplicity of infection (MOI) of 20 
under optimized protocols. Normalized enzymatic activity (ADA 
activity/vector copy) showed that LV EFS ADA had similar efficacy 
of transgene expression in murine ADA−/− HSCs compared with 
gRVSFada/W (Figure 1c). Similar levels of ADA protein expression 
were detected in ADA−/− HSC by western blot analysis (Figure 1d) 
and demonstrated that LV EFS ADA mediates efficient transduc-
tion and transgene expression in ADA−/− HSCs.
LV EFS ADA was also compared to another gRV used previously 
in a clinical trial, gRV MND-ADA,12 and an LV in which the MND 
LTR U3 enhancer/promoter controls ADA expression (LV MND-
ADA). Human cord blood CD34+ cells (CB HSC) were transduced 
with LV EFS ADA over a range of LV concentrations (106–108 TU/
ml; MOI = 10–1,000) and with gRVMND-ADA (generated from a 
stable PG13 cell clone) at 1.8 × 105 TU/ml. After short-term myeloid 
culture for 2 weeks, there was a significant dose-dependent trend 
between LV concentration during transduction and both the resul-
tant vector copy number (VCN) (P = 0.002) and ADA gene expres-
sion as measured by the ADA enzyme activity over background 
activity (P = 0.003) (Figure 1e,f). Transduction of CB HSC with 
each of the LVs at 1 × 107 TU/ml resulted in 1–3 vector copies per 
cell, and gRV MND-ADA, applied at a 100-fold lower dose, resulted 
in only ~0.2–0.8 copies per cell, but when normalized for VCN, 
activity was similar for LV EFS ADA and gRV MND-ADA (~1–2 
ADA U/VC) (Figure 1g). Although, ADA activity/VC was higher 
with LV MND-ADA (P = 0.03), it is not a preferred choice for clini-
cal HSC GT, as it harbors a strong gRV LTR enhancer/promoter 
which has increased mutagenic potential.29
Transplantation of LV EFS ADA transduced ADA−/− 
Lin- cells rescues lethality in ADA−/− mice
ADA−/− mice normally die within 3 weeks following withdrawal 
of PEG-ADA.5 We transplanted young adult ADA−/− mice with 
ADA−/− Lin- cells that had been transduced with either LV EFS 
ADA or SFada/W or with ADA+/+ Lin- cells (WT Lin-group). For 
all groups, PEG-ADA treatment was carried over for 4 weeks after 
transplantation to promote engraftment30 before complete with-
drawal. The survival rate was 100% in the LV EFS ADA group and 
the WT group, which was significantly higher than ADA−/− SFada/W 
group in which the survival rate was 40% (P = 0.02) (Figure 2a).
To evaluate integration of the viral vector and engraftment of 
donor cells in vivo, we performed quantitative polymerase chain 
reaction (qPCR) to evaluate VCN and male donor Y chromo-
some mononuclear cell (MNC) engraftment in PB at 13 weeks 
after transplantation. Similar levels of donor cells were present 
in the PB of the gRVSFada/W group (45.3 ± 0.4%) and WT Lin- 
(44 ± 21.7%) groups, while the level of donor cells was twofold less 
in the LV EFS ADA group (20.1 ± 2.5%) (Figure 2b). However, in 
the latter, VCN was 0.85 ± 0.16 copy/cell compared with 0.42 ± 0.2 
copy/cell in the gRVSFada/W group (Figure 2c).
Comparison of immune recovery after LV- and  
gRV-mediated gene delivery in ADA−/− mice
We then analyzed the total numbers of PB mononuclear cells 
(PBMC) and the percentages of lineage specific populations 
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within the mononuclear cell population (% of MNCs). Compared 
to all other groups, untreated ADA−/− mice had reduced num-
bers of total PBMCs and less than 10% of the MNCs were CD3+ 
(Figure 2d). In the LV EFS ADA or gRVSFada/W groups, more 
than 69% of the MNCs were CD3+, which included elevated levels 
of both single positive CD4+ and CD8+ cells which were similar 
to the levels observed in mice transplanted with WT HSCs (WT 
Lin- group) or age-matched mice under PEG-ADA treatment 
Figure 1 Viral constructs and transgene expression in murine lineage depleted bone marrow and human cord blood CD34+ cells. 
(a,b) Schematic representation of viral vectors. (a) Retroviral vectors (gRV): the γ-retroviral vector, MND-MFG-ADA (gRV MND ADA) contains the 
MND retroviral LTRs flanking the wild-type human adenosine deaminase cDNA (hADA) with the Moloney murine leukemia virus packaging region 
(Ψ) and env splice acceptor fragment (env SA). The gRVSFada/W vector contains hADA driven by SFFV LTR. (b) Lentiviral vectors (LV): All lentiviral 
vectors contain the enhancer-deleted “SIN” LTR (indicated by the X in the U3 region), the primer binding site (θ), the HIV-1 packaging signal (Ψ), 
the central polypurine tract (cPPT), the rev-responsive element (RRE). LV MND ADA contains the MND LTR U3 region enhancer/promoter (MND) 
driving expression of the hADA cDNA. LV EFS ADA contains the human elongation factor-α gene “short” promoter (EFS) driving expression of the 
codon-optimized human ADA cDNA (co-hADA) and a Woodchuck Hepatitis Virus posttranscriptional regulatory element (wPRE). The LV EFS GFP 
vector contains the EFS promoter and green fluorescent protein (GFP). (c,d) Murine ADA−/− bone marrow lineage negative (Lin-) progenitors were 
transduced for 24 hours with lentiviral or retroviral vectors at a multiplicity of infection (MOI) of 20 after 24 or 72 hours preactivation, respectively 
(Mean ± SD). ADA expression was analyzed 72 hours after transduction by (c) enzymatic activity assay and (d) Western Blot with whole cell lysates. 
Mean and standard deviation of ADA activities were calculated from experiments performed with cells obtained from three different ADA−/− donors. 
(e–g) Human cord blood CD34+ cells were transduced with the vectors at the indicated vector concentration, grown for 2 weeks in myeloid differ-
entiation culture, and assayed for (e) vector copy number (VCN) by quantitative polymerase chain reaction (qPCR) and for (f) ADA enzyme activity 
by colorimetric assay. (g) The ADA enzyme activity present per VC was calculated. Horizontal bars indicate Mean ± SEM.
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(ERT group). Although no significant improvement was detected 
in the percentage of B220+ cells with any treatment, taking into 
account the total cell numbers, the absolute number of B220+ cells 
in all transplants was much improved in comparison to untreated 
ADA−/− mice. In addition, GR-1+ myeloid cells and NK1.1+ cell 
numbers were corrected to relatively normal levels (data not 
shown).
To evaluate the development of the immune system upon 
ADA restoration, lymphoid organs including thymus and 
spleen were isolated from untreated and treated ADA−/− mice 
and lymphoid subpopulations were analyzed by flow cytometry. 
Overall, untreated ADA−/− mice had the lowest total cell numbers 
(Figure 2e), as well as the lowest CD3+ and B220+ percentages of 
total mononuclear cells, in the thymus and spleen (Figure 2f,g). In 
the thymus, the early CD4−CD8− population was twofold higher 
in untreated mice, highlighting the block in thymocyte develop-
ment found in ADA deficiency31 (Figure 2f, lower panel). In trans-
plants with LV- or gRV-transduced HSCs, we found significantly 
increased MNCs in all spleens (P < 0.05), and to a lesser extent, 
in thymi (P < 0.05) (Figure 2e). Among thymocytes, the CD3+ 
proportion was significantly elevated (P < 0.05). More impor-
tantly, the average percentage of CD4−CD8− double negative 
Figure 2 Survival rate, peripheral blood (PB) analysis, and immunophenotype of ADA−/− recipients. (a) Survival: Kaplan–Meier curves of ADA−/− 
recipients were transplanted with transduced ADA−/− BM Lin- cells (LV EFS ADA, n = 6) and gRVSFada/W (SFada/W, n = 5), respectively, at a multiplic-
ity of infection (MOI) of 20. Control mice were injected with untransduced BM Lin- cells from ADA+/+ donors (WT Lin-, n = 5). All LV EFS ADA and 
WT mice were alive at 13 weeks compared to gRVSFada/W group, where two mice died at 7 weeks and one died at 12 weeks with the remaining 
two alive at 13 weeks (P = 0.02). All surviving mice were euthanized for analysis unless otherwise indicated. (b) Percentage of donor cells in total PB 
mononuclear cells (PBMCs) by quantitative PCR (qPCR). (c) Vector copy number (VCN) in PBMCs of transplanted ADA−/− mice. Percentage of DNA 
with Y chromosome were evaluated in sex-mismatched transplants indicated in 1a (Mean ± SD). (d) FACS analysis of circulating mature T and B cells 
in peripheral blood of ADA−/− transplants. Untreated ADA−/− mice (untreated, 18 days old, n = 2) and 4–5 months old PEG-ADA treated ADA−/− mice 
(ERT, n = 2) were analyzed as controls. Data are displayed as percentage of CD3+, CD4+, CD8+, and B220+ cells in PBMCs. Horizontal bars indicate 
the average values. (e) Total mononucleated cell counts in thymi and spleens (*P < 0.001; **P < 0.05). Results are given as Mean ± SD. (f) FACS analy-
sis of thymocytes of ADA−/− recipients and control mice. Data are presented as percentage of total CD3+ and CD4−CD8− cells in mononucleated cells. 
Horizontal bars indicate the average values. (g) FACS analysis of splenocytes in ADA−/− recipients and control mice. Data are presented as percentage 
of CD3+ and B220+ cells in total mononucleated cells. Horizontal bars indicate the average values.
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thymocytes was reduced from 12% in untreated ADA−/− mice to 
only 4.6% in GT groups. This result demonstrates that the block 
in thymocyte development was overcome with restored ADA 
expression. In spleens of mice receiving transduced cells, there 
was an elevated percentage of CD3+ cells compared to untreated 
controls (P < 0.05) that was similar to WT transplants and mice 
treated with ERT alone (Figure 2g). B-cell percentages were simi-
lar to those in untreated mice but in relation to total cell number, 
there was a significant increase in absolute number of both CD3+ 
and B220+ cells in LV and gRV groups with no significant differ-
ence between these two groups (Figure 2e,g). These results sug-
gest that the proliferation and differentiation of both T and B cells 
has been restored in the GT groups at levels that were similar to 
the levels in the WT transplant and ERT groups.
Systemic detoxification following LV- and  
gRV-mediated gene delivery
In recipients with LV-transduced cells, we detected a twofold 
increase in VCN in thymus (0.2 ± 0.15), spleen (1.1 ± 0.34), mar-
row (0.44 ± 0.32) compared to those with gRV-transduced cells 
(Figure 3a). Donor cell engraftment was determined in mis-
matched sex transplants by qPCR for sequences on the Y chro-
mosome. The level of Y chromosome detected in the spleens of 
mice in the LV EFS ADA group was twofold lower (19.6 ± 2.0%) 
compared to the gRVSFada/W group. Likewise, the level of donor 
engraftment or level of Y chromosome in thymi from mice in 
the LV EFS ADA group were also twofold lower than those with 
gRVSFada/W, and ten fold lower than engraftment in the WT 
Lin- group (Figure 3b). Although donor engraftment appears to 
Figure 3 Engraftment of transduced cells, immune reconstitution, and systemic detoxification in ADA−/− recipients. (a) Vector copy number 
analysis of thymus, spleen, and bone marrow in ADA−/− recipients. (Mean ± SD). (b) Percentage of donor cells in thymus, spleen, and bone marrow by 
quantitative PCR (qPCR). Percentage of DNA with Y chromosome were evaluated in sex-mismatched transplants indicated in 1a (Mean ± SD). (c) ADA 
activity and (d) SAHH activity in red blood cells, BM cells, thymocytes, and lung tissue of ADA−/− transplants and control mice were measured by enzy-
matic activity assay as indicated (Mean ± SD). (e) Histopathologic analysis of lung sections from ADA−/− transplanted with ADA−/− Lin- gRVSFada/W or 
ADA−/− Lin- LV EFS ADA or ADA+/+ WT Lin- cells compared to lung sections from 18-day-old untreated ADA−/− and ADA−/− mice under ERT (ADA−/− ERT) 
mice. All sections have been stained with hematoxylin and eosin.
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be lower with transduced (LV or gRV) cells, this may represent 
dilution of the transplanted donor cells with the host cells that 
are crosscorrected by the overexpression of ADA from the vec-
tor in the primary lymphoid organs. This dilution effect has been 
described previously and is specific to ADA-SCID because there is 
crosscorrection of uncorrected ADA-deficient cells with adequate 
ADA activity provided by ERT, HSCT, or GT.30
ADA−/− mice have undetectable ADA enzyme activity and 
decreased SAHH activity in most tissues and organs.5 To confirm the 
expression of functional ADA by LV EFS ADA and gRVSFada/W in 
vivo, we analyzed ADA and SAHH activities in multiple systems 
including nonlymphoid organs such as the lung (Figure 3c,d). In 
PB and lymphoid organs including spleen and thymus, ADA activi-
ties in the LV EFS ADA and gRVSFada/W groups were comparable 
to activities in WT Lin- transplantation group in (Figure 3c), which 
is noteworthy given the engraftment of transduced ADA−/− donor 
cells in the thymus was measured to be ten fold lower compared to 
ADA+/+ WT Lin- donor cells (Figure 3b).
In a nonimmune organ, such as the lung, ADA enzymatic 
activity was also equivalent in all GT treated mice in comparison 
to WT transplants and undetectable in untreated mice (P < 0.05). 
Similar ADA activities were also found in livers of the transplants 
(data not shown). Inhibition of S-adenosyl homocysteine hydro-
lase (SAHH) activity is secondary to the accumulation of dATP 
in ADA-deficient mice.5 In all transplants, untreated mice showed 
absent or low levels of SAHH activity in RBC, thymus, spleen, 
BM, and lung, whereas LV GT treated mice showed increased 
SAHH activity to levels similar to the WT Lin-–treated mice (P < 
0.05) (Figure 3d). These results demonstrate that LV EFS ADA–
mediated gene transfer can lead to efficient metabolic correction 
in the ADA-deficient mouse that is comparable to correction with 
gRVSFada/W and WT Lin- HSCT.
We also studied other organ pathologies in untreated and 
treated mice. Nonlymphoid organs including lung, liver, heart, 
and kidney were harvested and examined histologically. The 
dominant pathologic improvements were observed in the lungs of 
treated mice (Figure 3e). Untreated ADA−/− mice show occlusion 
of the airways and thickening of airway epithelium with accumu-
lation in the airspaces of proteinaceous material and infiltration 
of alveolar macrophages. There was a striking improvement in 
all treatment groups, including LV EFS ADA and gRVSFada/W 
groups, with clearance of interstitial fluid and absence of inflam-
matory cells with lung histology similar to that seen in ADA−/− WT 
Lin- mice. There were no predominant findings in the structure or 
organization of other organs in untreated and treated mice (data 
not shown).
LV EFS ADA transduction and expression is dose-
dependent in human HSC
Human CD34+ cells were isolated from multiple samples of nor-
mal ADA-replete human CB (CB HSC) (n = 5) and BM (BM 
HSC) (n = 4), and BM from infants with ADA-deficient SCID 
(ADA-SCID HSC) (3-month-old (n = 2) and 9-month-old (n = 1) 
donors). The prestimulated CD34+ cells were either transduced 
with LV EFS ADA over a range of vector concentrations (1 × 106 
to 1 × 108 TU/ml), corresponding to a range of MOI of 10–1,000, 
or mock transduced, and analyzed after 14-day culture. There was 
a significant dose-dependent relationship between the LV EFS 
ADA concentration during transduction and the resultant VCN 
in CB HSC (P = 0.012) and ADA-SCID HSC (P = 0.004), but not 
in BM HSC (Supplementary Figure S1a). Similarly, there were 
significant dose-dependent correlations between the LV EFS ADA 
vector concentration during transduction and the resultant ADA 
expression (ADA activity over background) in CB HSC (P = 0.03) 
and infant ADA-SCID HSC (P = 0.002), but not in adult BM HSC 
(Supplementary Figure S1b).
The endogenous ADA enzyme activity measured in mock-
transduced ADA-deficient BM cells from the several experiments 
was 10- to 30-fold lower (Mean ± SEM: 0.05 ± 0.02 U) than in 
mock-transduced normal CB cells (Mean ± SEM: 0.54 ± 0.07 U) 
(P = 0.029) or mock-transduced normal BM cells (Mean ± SEM: 
1.6 ± 0.82 U) (P < 0.0001) (Supplementary Figure S1c). Across all 
vector concentrations and MOIs used for transduction by LV EFS 
ADA, the expression of ADA enzyme activity normalized to sin-
gle vector copy was 1.69 ± 0.15 U/VC in the normal CB samples; 
1.67 ± 0.33 U/VC in the normal BM samples; and 1.2 ± 0.10 U/VC 
in the ADA-deficient BM samples (Supplementary Figure S1d). 
The ADA activity in the LV EFS ADA–transduced ADA-deficient 
SCID BM cells was 24-fold higher than endogenous levels in 
the mock-transduced samples; ADA activity in LV EFS ADA–
transduced normal donor CB and BM HSC was one- to threefold 
over endogenous levels in mock-transduced ADA-replete donor 
samples (Table 1).
LV EFS ADA lentiviral transduction and engraftment 
of human CB HSC and the role of IL-3
To further evaluate LV EFS ADA and to gain insight into the 
effects of IL-3 on LV transduction of human HSC, we compared 
transduction and long-term engraftment of the CB CD34+ cells, 
with and without IL-3 included in the prestimulation and trans-
duction media. CB HSC (n = 2) were thawed, plated (500,000 cell/
ml), and prestimulated for 20 hours in medium containing human 
stem cell factor, human FLT3-L and human TPO (S/F/T), with or 
Table 1 ADA enzyme activity after 2-week in vitro myeloid culture: endogenous in human hematopoietic cells and expressed by EFS-ADA after 
CD34+ cell transduction
Human CD34+ cell source
ADA enzyme activity
Mock transduced ADA 
activity (U) mean ± SEM
EFS-ADA transduced ADA 
activity/VC (U/VC) mean ± SEM
EFS-ADA (U/VC)/
endogenous (U)
Normal cord blood 0.54 ± 0.05 (n = 6) 1.69 ± 0.15 (n = 16) 3.12
Normal bone marrow 1.63 ± 0.63 (n = 5) 1.35 ± 0.22 (n = 17) 0.82
ADA SCID bone marrow 0.05 ± 0.02 (n = 7) 1.21 ± 0.10 (n = 30) 24.2
ADA, adenosine deaminase; SCID, severe combined immunodeficiency.
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without IL-3 (20 ng/ml). The prestimulated cells were transduced 
with LV EFS ADA (3.0 × 107 TU/ml) or mock transduced. To test 
the effects of IL-3 exposure on the engraftment of more primitive 
stem/progenitor cells, LV EFS ADA–transduced or mock-trans-
duced CD34+ cells were xenotransplanted into Nod/SCID/γ C 
(NSG) primary and secondary mouse recipients.
The VCN measured after 14-day short-term culture was 
twofold higher with IL-3 (2.5 ± 0.8) compared to without IL-3 
(1.2 ± 0.4), but this difference was not significant (Figure 4a). 
Likewise, there were no significant differences in the total num-
bers of colony-forming units (CFUs) produced per 1,000 plated 
CD34+ cells in the LV-transduced group (no IL-3: 87/1,000 = 
8.7%, with IL-3: 109/1,000 = 10.9%) compared to the mocktrans-
duced (no IL-3: 109/1,000 = 10.9%, with IL-3: 83/1,000 = 8.3), nor 
in the different types of colonies formed (Figure 4b,c). Although 
inclusion or exclusion of IL-3 did not make a significant difference 
in the percentage of CFU colonies containing LV sequences 
(39.3% with IL-3 versus 31.1% without IL-3), the mean VCN in 
DNA from individual CFU was 3.1-fold higher when IL-3 was 
included (15.1 ± 2.1) than when it was not (4.9 ± 10) (P = 0.001) 
including, a subset of CFU with an average VCN > 10 only when 
exposed to IL-3 (Figure 4d,e).
Between postnatal day 1 and 3, sublethally irradiated (150cGy) 
NSG neonates were transplanted with 100,000 CB CD34+ cells 
(IV), either mock-transduced with IL-3 (n = 5) or without (n = 5), 
or transduced with LV EFS ADA with IL-3 (n = 13) and without 
IL-3 (n = 14). Engraftment was not different in tissues isolated 
from mice transplanted with LV EFS ADA transduced or mock-
transduced human CD34+ cells, with or without IL-3 (Figure 4f). 
VCN was measured in bone marrow, thymus, and spleen and cor-
rected for the level of engraftment (FACs for huCD45) and was not 
different in tissues isolated from mice transplanted with LV EFS 
Figure 4 The role of IL-3 in EFS-ADA lentiviral transduction of human cord blood CD34+ cells and engraftment in NSG mice. Human cord 
blood CD34+ cells were transduced with LV EFS-ADA (3 × 107 TU/ml) in medium with recombinant human cytokines SCF/ckit ligand, flt-3 ligand, and 
thrombopoietin (TPO), with or without interleukin-3 (IL-3). (a-d) In vitro: (a) transduced cells cultured for 14 days in vitro under myeloid differentia-
tion conditions and analyzed for VCN (14d VCN) (N.S, not significant). (b,c) Transduced CD34+ cells were grown in colony-forming unit (CFU) assay 
in methylcellulose and assayed after 2 weeks. Colony (b) enumeration and (c) types formed by CD34+ cells in CFU assay. (d,e) CFU were harvested 
and DNA analyzed by qPCR for VCN (d) Transduction efficiency was measured by the percentage of colonies positive for vector sequence by PCR 
for the human ADA cDNA (%PCR (+) CFU). (e) VCN was quantified in DNA extracted from individual CFU by qPCR (*P value = 0.001). (f-h) In Vivo: 
other portions of the transduced CD34+ cells were transplanted into NSG mice and analyzed after 4 months for engraftment of human cells based 
on FACS analysis of huCD45 expression and for VCN by qPCR. Engraftment of human cells in (f) bone marrow, thymus (when present) and spleen 
by FACS of tissue cell suspensions immunostained with anti-human CD45 (%hCD45+). (g) EFS-ADA VCN in bone marrow, thymus (when enough 
cells were available for analysis; total n = 3),and spleen. (h) Immunophenotypic analysis of human CD45+ cells in NSG bone marrow (CD34+ and 
CD33+), thymus (CD4−/CD8− double-negative (DN), CD4+/CD8+ double-positive (DP), CD4+ single-positive (SP-4) and CD8+ single-positive (SP-8)) 
and spleen (CD19+ and CD3+).
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ADA transduced with or without IL-3 (Figure 4g). There were 
no significant differences in the lineages of the engrafted human 
cells in the BM (CD34 and CD33), spleen (CD19 and CD3), and 
thymus (DN, DP, SP-4, SP-8) in any of the groups (Figure 4h). 
Unfortunately, only 1 out of a total of 35 secondary adult recipient 
mice from two separate experiments had human cell engraftment, 
and therefore, we were unable to determine any effects of IL-3 on 
HSC transduction at the most primitive stem cell level.
LV EFS ADA transduction of human ADA-deficient 
SCID BM HSC
We further evaluated LV EFS ADA for transduction efficacy, 
engraftment, and differentiation in human ADA-deficient SCID 
BM CD34+ cells (ADA-SCID HSC). ADA-SCID HSC were freshly 
isolated and transduced with LV EFS ADA at 3.3 × 107 TU/ml or 
mock transduced (n = 3) and analyzed in parallel by in vitro assays 
and in vivo by transplantation into NSG neonates. CFU assays in 
methylcellulose were enumerated and characterized by their mor-
phology for lineage type after 12 days. The LV- and mock-trans-
duced cells grew similar numbers and types of colonies: LV EFS 
ADA 289 colonies/14,000 cells plated (2.1%); mock transduced 
50 colonies/2,000 cells plated (2.5%) (Figure 5a,b). Colonies that 
grew from the LV EFS ADA–transduced cells (n = 2) were 95% 
positive for the LV vector sequence (Figure 5c). After short-term 
in vitro myeloid culture, LV EFS ADA–transduced cells had a 
mean ADA activity of 4.6 ± 1.4 U, which was >92-fold higher than 
the background ADA activity of mock-transduced ADA-deficient 
cells (0.05 ± 0.02 U; one-sided P = 0.03) (Figure 5d). The LV 
EFS ADA–transduced cells had a mean VCN of 2.92 ± 0.75 and 
expressed 1.55 ± 0.22 ADA U/VC.
Figure 5 EFS-ADA transduction of normal and ADA-deficient human cord blood and bone marrow CD34+ cells analyzed in vitro and in vivo. 
ADA-deficient severe combined immunodeficiency (SCID) bone marrow CD34+ cells from two donors in three separate experiments were isolated 
and transduced with the EFS-ADA vector at 3 × 107 TU/ml or mock-transduced, cultured in short-term myeloid culture for 2 weeks and then harvested 
and analyzed. (a–c). In vitro: CFU progenitor assays. (a) Enumeration of lineage committed progenitors (b) the frequency of colonies of different 
lineages. (c) Transduction efficiency determined by the presence of vector sequence in DNA from isolated colonies. (d) In vitro ADA activity (U) 
measured in mock-transduced and in EFS-ADA transduced bone marrow CD34+ cells and the VCN and expressed ADA activity (U)/VC measured in 
the EFS-ADA transduced cultures. (e–i) In Vivo: NSG humanized mice. (e) Engraftment of human (%hCD45+) cells in the bone marrow, thymus, and 
spleen of NSG mice 4 months after transplantation with mock-transduced or EFS-ADA-transduced human ADA-deficient SCID bone marrow CD34+ 
cells. (f) Human CD45+ leukocyte populations by immunophenotype in bone marrow, thymus, and spleens from NSG mice (g) ADA enzyme activity 
(U) (h) EFS-ADA VCN and (I) ADA activity (U)/VC) in cells isolated from the bone marrow (huCD45-selected), thymus (total thymocytes), and spleen 
(huCD45-selected).
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Four months after HSCT of ADA-SCID HSC into NSG mice, 
engraftment of human cells varied considerably among recipients 
(2–90%) but was not different with LV EFS ADA compared to 
mock-transduced cells in bone marrow (mock 31.2%; LV 28.7%), 
spleen (mock 28.9%; LV 34.7%), or thymus (mock 95.9%; LV 
90.0%) (Figure 5e). Notably, transduction by the LV EFS ADA 
vector did not impair differentiation of the ADA-SCID HSC. In 
the bone marrow of mice transplanted with mock-transduced 
cells, 9.5% (±1.2) of the human CD45+ cells expressed the hema-
topoietic stem/progenitor cell marker CD34 compared to 8.5% 
(±1.3) in mice transplanted with LV EFS ADA–transduced cells. 
Similarly, myeloid markers CD14 and CD11b were expressed on 
7.3% (±4.5) and 10.4% (±4.4) of the human CD45+ cells from 
mice transplanted with mock-transduced and LV EFS ADA–
transduced cells, respectively (Figure 5f).
Thymocytes isolated from recipients of LV EFS ADA–
transduced ADA-SCID HSC had typical proportions of CD4/CD8 
double-negative (10.7%), CD4/CD8 double-positive (54.6%), 
CD4 single-positive (10.1%), and CD8 single-positive cells 
(24.6%) (Figure 5f). In contrast, thymocytes isolated from recipi-
ents of mock-transduced ADA-deficient CD34+ cells had typical 
proportions of only CD4/CD8 double-negatives (12.4%) and CD4 
single-positive cells (11.7%), but had significantly more CD8 sin-
gle-positive cells, (64.7%; P = 0.020) and significantly less double-
positive cells (11.2%; P = 0.028) compared to mock transduced, 
suggesting abnormal thymopoiesis without ADA gene correction. 
In mature lymphocyte populations, there was no difference in the 
percentages of splenic CD3+ human T cells produced from the 
LV-transduced cells (13.2%) or mock-transduced cells (18.7%), 
but there was a higher percentage of splenic CD19+ human B cells 
produced from the LV-transduced cells (68.8%) compared to the 
mock-transduced cells (51.6%) (P = 0.047).
ADA enzyme activity was analyzed in enriched populations of 
human CD45+ cells isolated from the bone marrow and spleen, 
and from total thymocytes of the NSG mice. The mean ADA 
activity in thymocytes was 0.05 ± 0.01 U from mice transplanted 
with mock-transduced cells and was 0.52 ± 0.30 U from mice 
transplanted with LV EFS ADA–transduced cells (Figure 5g). The 
relatively high ADA activity detected in mock transduced BM and 
spleen most likely derive from the murine cells, which are replete 
for ADA expression, contaminating the human CD45-enriched 
populations. VCN consistently averaged between 3.7 and 5.2 VC 
per cell in the three organs analyzed, with 1.3–1.8 U/VC ADA 
enzyme expression (Figure 5h,i).
LV EFS ADA shows significantly decreased 
transformation potential in comparison to gRV 
vectors
A major concern regarding the continued clinical use of gRV is 
the risk of insertional mutagenesis. The in vitro immortalization 
(IVIM) assay has demonstrated the capability to detect transfor-
mation of virally transduced cells under myeloid differentiation 
conditions.25 In two independent studies, performed in the United 
Kingdom and in the United States, we adopted this approach and 
compared the LV EFS ADA to the gRVSFada/W and gRV MND-
ADA vectors. A second vector using the promoter/enhancer ele-
ment of spleen focus-forming virus driving the green fluorescent 
protein reporter gene (gRVSF91GFP) was also used as a positive 
control in both studies. In the UK study, another positive control 
was included using a SIN LV design but with an internal SFFV 
promoter (LV SF GFP). In both studies, cells were also subject to 
mock transduction in similar culture conditions to monitor back-
ground activity.
In the UK study, the gRV SF91 GFP vector induced positive 
replating clones in all experiments and the LV SF GFP vector 
did so in two out of four experiments. Most notably, the clinical 
gRVSFada/W vector also displayed positive replating activity in 
all experiments, suggesting that this vector has strong transforma-
tion ability. The LV EFS ADA–transduced cells did not produce 
clones with higher proliferative capacity than mock-transduced 
cells in any of the four independent experiments (Figure 6a). The 
replating index (replating frequency/VCN) was calculated and, 
both gRVSF91GFP and gRVSFada/W vectors had high replating 
indices. The LV SF GFP vector harboring internal SFFV promoter 
displayed a relative lower replating index than gRVs. Importantly, 
the LV EFS ADA vector generated no detectable mutants result-
ing in a negative replating index. In a modification of previously 
described IVIM assays,28 cell proliferation was detected using 
the WST-1 assay method (IVIM-WST1 assay), in which viable 
cell numbers were determined by the measurement of products 
generated from cleavage of WST-1 by mitochondrial dehydroge-
nases thereby allowing a quantitative assessment of the growth of 
replating clones. Four independent experiments were conducted 
and the highest reading from mock-transduced clones was set as 
the threshold, values above which were regarded as positive clones 
(Supplementary Figure S2).
In the US study, four independent experiments (13 assays) 
were conducted. The gRVSF91.GFP and gRVMND-ADA retrovi-
ral vectors produced abundant immortalized clones, with replat-
ing frequencies/VCN of 3.36 × 10−3 (or 1 in 306) and 3.68 × 10−4 
(or 1 in 2,717), respectively. No colonies were formed by the 
mock-transduced or the LV EFS ADA–transduced cells across 
all 13 assays performed. The frequency of replating by LV EFS 
ADA was significantly lower when compared to gRV SF91.GFP, 
(P < 0.001) and when compared to gRVMND-ADA (P < 0.001; by 
two sample nonparametric Wilcoxon rank sum test) (Figure 6b; 
Supplementary Table S1).
The distribution of unique vector integration sites was deter-
mined in LV EFS ADA–transduced human BM and CB CD34+ 
cells prior to transplant (in vitro) and in cells from the BM of 
NSG mice 4 months after transplantation (in vivo). LV EFS ADA 
integration patterns seen in the human cells after the short-term 
culture and in the cells after xenografting in vivo were essentially 
identical, with no in vivo clonal skewing toward a higher frequency 
of vector integrants in cancer-associated genes (Figure 6c), and 
no dominant clones observed and also no increase of integrants 
near the 5′ transcriptional start sites of genes (Figure 6d).
DISCUSSION
While past clinical studies using gRV for GT of ADA-deficient 
SCID have provided clear clinical benefit, the level of immune 
recovery has, in general been, suboptimal; with T-cell numbers at 
the lower end of the normal range and less than 50% of patients 
being able to stop immunoglobulin replacement.12,13 Furthermore, 
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although success has been achieved with no transformation 
events using gRVs, the potential concern regarding vector-medi-
ated leukemogenesis has remained. Thus, improvement of clini-
cal outcomes and increased safety concerns has necessitated the 
development of more efficacious and safer vector designs. Ideally, 
a new vector for future clinical trials for the treatment of ADA-
SCID should achieve the following: efficient ADA gene transfer 
to HSC, high and consistent ADA enzyme activity with low VCN, 
reduced probability of acute cytotoxicity or genotoxicity, and 
improved immune reconstitution. In an attempt to fulfill these 
requirements, we developed and compared the LV EFS ADA vec-
tor, in which the codon-optimized hADA cDNA is driven by an 
internal mammalian EFS promoter in a SIN-configuration back-
ground (LV EFS ADA), to the gRV ADA vectors that have been 
used successfully in ADA GT clinical trials. In our studies, LV 
EFS ADA led to efficient transduction of HSCs with shortened 
ex vivo culture time, delivered therapeutic levels of ADA trans-
gene expression via progenitor cells into multiple differentiated 
lineages, rescued ADA−/− mice from lethality and corrected 
immune system and metabolic abnormalities. Most importantly, 
the LV EFS ADA vector showed a significant reduction in trans-
formation potential.
The level of ADA expression is likely to be important in allow-
ing full correction of the disease. In the LV EFS ADA vector, we 
used a codon-optimized version of the human ADA cDNA to 
maximize expression and biological activity of transgene, in com-
bination with the internal intron-deleted EFS promoter. Because 
this shortened version of the human elongation factor 1-α pro-
moter lacks its strong enhancer, expression may be reduced com-
pared to the viral SFFV enhancer/promoter. Nevertheless, LV EFS 
ADA achieved high ADA expression and activity with low VCN 
in LV EFS ADA transduced human HSC in vitro and in murine 
lineage depleted progenitors at levels comparable to those trans-
duced with the gRVs containing viral enhancers. Vectors with this 
EFS promoter have been shown to have a significantly decreased 
risk of insertional mutagenesis in both in vitro and in vivo models 
Figure 6 Assessments of genotoxicity of EFS-ADA lentiviral vector. In vitro immortalization (IVIM) Assay. Murine Lin- cells transduced by the 
indicated vectors were expanded as mass cultures for 2 weeks. An aliquot was taken for qPCR for VCN measurement. On day 15, cells were 
plated into 96-well plates at a density of 100 cells/well or 1,000 cells/well in 100 µl medium. Two weeks later, the wells showing abundant cell 
growth were counted as positive, and the frequency of replating cells was calculated based on Poisson statistics using L-Calc Software (Stemcell 
Technologies, Vancouver, Canada). Horizontal bars indicate mean values. (a) Replating frequency corrected for VCN group by investigators at GOSH, 
UK. (b) Replating frequency corrected for VCN group by investigators at University of California, Los Angeles, USA (c,d) Vector integration site analy-
sis in human ADA-deficient bone marrow in vitro and in vivo. (c) The percentages of unique integration sites in human cells (isolated from primary 
NSG mouse recipient bone marrow) near cancer-related genes were determined in vitro (n = 9,822 unique sites) or in vivo (n = 3,141 unique sites). 
Integration sites in genes or within 300 kb of gene TSS were considered “near” and cancer-related genes were defined as in Higgins et al. 40.(d) The 
EFS-ADA vector integration sites were mapped relative to transcriptional start sites (TSS) in vitro (n = 1,610 unique sites) and in vivo (n = 517), and 
compared to a published data set for MLV1 (n = 828). Grey line represents the theoretical random distribution (n = 12,837).
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of transformation.32,33 Clinical trials of GT for SCID-X1 using this 
promoter are currently ongoing with no evidence of clonal domi-
nance thus far (Thrasher, personal communication).
Since studies in vitro demonstrated that LV EFS ADA had 
ADA activity/VCN comparable to that from the gRVSFada/W 
and the gRV MND-ADA vector, we progressed to test the vec-
tor in comparative studies in in vivo models of ADA deficiency. 
The murine ADA−/− model is a highly representative model of the 
human disease, as untreated mice display severe lymphopenia 
before dying in the first 3 weeks of life from pulmonary insuf-
ficiency, which arises from the metabolic consequences of the 
disease.5 Correction of the murine disease phenotype by ADA 
delivery through a variety of GT or ERT approaches has previ-
ously been demonstrated and thus this is an appropriate model to 
test and compare the efficacy of the LV EFS ADA vector.30,34
In ADA−/− murine transplant experiments, ERT was contin-
ued for 4 weeks prior to complete withdrawal. Previous studies 
have demonstrated that ongoing use of PEG-ADA does not inhibit 
gene-modified cell engraftment and improves thymic reconstitu-
tion.30 Although we did not perform comparative studies with 
cohorts where ERT had been withdrawn prior to GT, the levels 
of engraftment and immune reconstitution in our GT treated 
mice cohorts were similar to those achieved in the WT transplant 
cohort and demonstrate that the short-term use of PEG-ADA 
post-GT was not detrimental to gene-modified cell engraftment.
After PEG-ADA withdrawal, we only observed deaths in the 
gRV group, while none were seen in the groups transplanted with 
LV-transduced or WT cells, indicating that sufficient intracellular 
ADA production was achieved through gene transfer to correct 
the pulmonary insufficiency, which is the primary cause of death 
in deficient animals. Histological analysis of the lungs showed 
clearance of inflammatory cells and interstitial material and bio-
chemical analysis of lung tissue showed restoration of ADA and 
SAHH activity. Similar less severe noninfectious pulmonary man-
ifestations have been observed in ADA-deficient patients35, and 
thus these data are encouraging in demonstrating the effect of GT 
to correct this nonimmunological manifestation of the disease. 
All surviving mice also had engraftment of donor gene modified 
(LV and gRV) cells with comparable VCN in all tissues analyzed 
and showed evidence of metabolic correction with increased 
ADA activity and SAHH activity, which indirectly reflects low-
ered dATP levels in reconstituted mice. The death of mice in the 
gRV group is likely to be due to the lower engraftment of gene-
modified cells in these mice. Animals that died before analysis had 
lower VCN (<0.1 copy/cell) than the survivors (0.2–0.6 copy/cell). 
Histopathological examination of deceased mice demonstrated 
evidence of airway thickening and obstructions in lung.
All cohorts including GT treated, WT treated, and ERT treated 
ADA−/− mice displayed equivalent levels of immune recovery as 
reflected by the numbers of total lymphocyte counts and specific 
subpopulations. Overall, the performance of the LV EFS ADA 
vector in reconstituting the ADA−/− mouse was comparable to that 
of gRVSFada/W and gRV MND-ADA and given that these vec-
tors have been used successfully in promoting long-term immune 
recovery and metabolic correction in human subjects,11–13 these 
findings generate confidence that the LV EFS ADA vector will 
also be able to promote similar recovery in the clinical setting. 
However, this hypothesis is difficult to test in animal models and 
can only be determined in the context of clinical trials.
LV EFS ADA was characterized further by transducing pri-
mary human CD34+ cells from normal CB, normal donor BM 
and, most relevantly, from BM samples from ADA-deficient SCID 
infants. Efficient vector dose-related transduction of CD34+ cells 
was achieved, with VCN ranging from 0.1 to 10, using concentra-
tions of LV EFS ADA between 1 × 106 and 1 × 108 TU/ml. Vector 
concentrations of 1–5 × 107 TU/ml led to 1–3 VCN when analyzed 
by in vitro assay or in vivo in the NSG mice, which would be an 
ideal VCN in the clinical setting to achieve the maximal percent-
age of gene-corrected HSC without reaching excessive burdens of 
integrated vectors.
ADA expression by the LV EFS ADA was quite consistent 
across all studies performed, producing 1–3 times of normal 
ADA activity per single vector copy in the cells from short-term 
myeloid culture and in human CD45+ leukocytes, including thy-
mic T cells, produced in vivo by engraftment of transduced ADA 
SCID HSC in NSG mice. Expression by LV EFS ADA was main-
tained essentially unchanged after in vivo growth. This level of 
ADA enzyme expression at low VCN indicates that the LV EFS 
ADA should have therapeutic effect, as a relatively broad range 
of ADA activity is tolerated and supports immune reconstitution.
In further evaluating LV EFS ADA, we also assessed the role 
of IL-3 in supporting HSC transduction, as the benefits of includ-
ing IL-3 in the cytokine cocktail has been of uncertain value.36,37 
The addition of IL-3 to the relatively standard combination of 
cytokines (S/F/T) increased the average VCN in CD34+ cells 
when analyzed after short-term myeloid culture and in CFUs. 
However, there were no long-term effects of IL-3 on human HSC 
engraftment, differentiation or vector transduction using the NSG 
xenograft model, suggesting that the increased VCN measured 
in short-term bulk cultures and CFUs was primarily the result 
of a subset of the progenitors receiving increased copies of the 
vector, rather than significant transduction of additional cells. 
Alternatively, high VCN could be toxic in the long term, leading 
to loss of the highly transduced clones in vivo.
The lack of effects of IL-3 on HSC is consistent with the 
absence of its receptor (IL3Ra) on primitive human HSC.38 Thus, 
IL-3 seems to exert its effects on the transduction of committed 
clonogenic progenitors, which are read-out in short-term assays 
but has no apparent effect on long-term repopulating cells. In the 
clinical setting, there may be some advantage to higher transduc-
tion of short-term progenitors to provide early expansion of cells 
expressing ADA during the several months required for long-term 
HSC to produce lymphocytes de novo.30 Of the many (>40) ADA 
SCID patients treated previously in clinical trials, some received 
cells that were transduced in the presence of IL-311,13 and others 
did not,12 yet the majority realized long-term effective immune 
recovery without any evidence of lymphoproliferation or other 
adverse events. The results presented in this manuscript do not 
make any strong argument for removing IL-3 from the transduc-
tion protocol, and therefore to avoid multiple protocol changes, 
the forthcoming trial with LV EFS ADA will also use IL-3 as part 
of the transduction cytokine cocktail.
Although there have been no insertional oncogenic events 
using gRV for GT of ADA-deficient SCID in more than 40 treated 
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subjects, there have been several oncogenic events in other tri-
als using HSC-directed GT to treat immunodeficiencies.14,15,17,19 
Furthermore, the safety issue related to the gRVSFada/W has been 
a concern particularly after common insertion sites have been 
identified in the MDS1/Evi1 locus in two ADA SCID patients after 
GT although no malignancies have developed so far (data not 
shown). To address these concerns, we used a SIN LV designed 
to reduce the risk of insertional mutagenesis, as this configuration 
has already been shown to be safer in other studies.24,25,39
To test this specific LV EFS ADA vector, we have used the in 
vitro platform established by Modlich et al.,25 to assess the in vitro 
insertional mutagenesis potential of the vectors. The dramatically 
reduced incidence of transformants in LV EFS ADA transduced 
cells (no clonal outgrowth observed across multiple assays), in two 
independent studies, strongly indicates that this LV has signifi-
cantly reduced genotoxicity compared to the gRVSFada/W or gRV 
MND-ADA used in prior trials at least in this assay. The improved 
safety property of LV EFS ADA can be attributed to the SIN design 
and use of internal mammalian EFS promoter, which reduces the 
risk of enhancer-mediated neighboring gene transactivation. The 
integration profile of the LV EFS ADA is also more frequent into 
active transcribed genes but is not concentrated on promoter-prox-
imal areas.40–42 Indeed, the lack of skewing of LV EFS ADA integra-
tion sites during in vivo growth of transduced human CD34+ cells 
in NGS mice is consistent with other reports of undetectable geno-
toxicity from similar LVs in in vitro assays. Clinical trials using SIN 
LVS are already underway for a number of monogenic diseases of 
the bone marrow including immunodeficiencies and metabolic 
diseases, and the data thus far show a polyclonal pattern of vector 
integration with no evidence of clonal dominance.26,43,44
Taken together, these studies demonstrate that LV EFS ADA 
has the potential fulfill the requirements deemed essential to pro-
vide increased safety and clinical benefit for ADA SCID patients. 
Based on these data presented here, two clinical trials using autol-
ogous BM or PBSCs HSC transduced with LV EFS ADA, have 
recently been initiated, one in the United Kingdom (University 
College London, London) following approval by GT Advisory 
Committee (GTAC) and Medicines and Healthcare Products 
Regulatory Agency (MHRA) (EudraCT No: 2010-024253-36) and 
one in the United States. (University of California, Los Angeles, 
Los Angeles and the National Institutes of Health, Bethesda) fol-
lowing approval by the US Food and Drug Administration (FDA; 
IND #BB15440; ClinicalTrials.gov NCT#01852071). These studies 
will allow us to determine the efficacy and safety of LV EFS ADA 
in the clinical setting and to see if LV EFS ADA can provide more 
effective HSC transduction and engraftment than that observed in 
gRV studies, and result in more rapid and robust immune recon-
stitution without genotoxicity.
MATERIALS AND METHODS
Experimental animals. All animals were handled in laminar flow hoods 
and housed in microinsulator cages in pathogen-free colonies. Animal 
procedures and housing were in accordance with Home Office animal 
welfare legislation at University College London (UCL) in the United 
Kingdom, and in accordance with the Animal Research Committee and 
Division of Laboratory Animal Medicine and the National Institutes of 
Health guidelines at University of California, Los Angeles (UCLA) in the 
United States.
ADA mice. The ADA colony, maintained at UCL (FVB; 129-Adatm1Mw 
Tg(PLADA)4118Rkmb/J) was purchased from the Jackson Laboratory 
(Bar Harbor, ME) and was described previously.5 ADA+/+ and ADA−/− 
mice were generated by intercrossing ADA+/− females with ADA+/− males. 
Progeny were genotyped by polymerase chain reaction (PCR) assay (http://
jaxmice.jax.org). ADA−/− mice were maintained by weekly intraperitoneal 
injection (i.p.) of PEG-ADA (kind gift from Sigma-Tau Pharmaceuticals) 
at a dose of 1,000 units/kg until transplanted and then remained on ERT 
for 1 month after transplant.30
NSG mice : The NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ strain (NSG) was 
purchased from the Jackson Laboratory (Bar Harbor, MA) in UCLA and 
were bred as mutant pairs.45
C57BL/6 mice. For IVIM assays at UCL and UCLA, 7-week-old C57BL/6 
inbred mice were purchased from Harlan Laboratories (UK) and from 
Jackson Laboratory.
Viral vector construction. The LV EFS ADA vector was constructed 
as described before28 at UCL. Briefly, a codon-optimized human ADA 
cDNA sequence linked with an EFS fragment was inserted into ClaI/
SalI sites in the pCCLsincpptW1.6hWasp-WPRE backbone. The LV 
MND-ADA was constructed by inserted a blunted Hind III human ADA 
cDNA fragment into the SmaI site of pCCLc-MNDU3-X2 backbone, 
which contains the retroviral MND LTR U3 region driving expression 
of human ADAcDNA.
The SFada/W vector was described in Gaspar et al.,46 with a wild-type 
human ADA cDNA controlled by the gRV SFFV LTR. The gRV MND-
ADA was constructed as described in Candotti et al.,12 and contains the 
human ADA cDNA under the control of the MND LTR. The LV EFS 
GFP vector was cloned with a HincII/BamHI fragment containing EFS 
promoter into the P’HR-cppt-SEW (LV SF GFP) vector.47 The gRV SF91 
GFP vector was a kind gift from Professor Christopher Baum.48
Viral vector production and titer determination
LV. The LVs were packaged in HEK293 T cells by triple transfection of 
the packaging plasmids pMD.G2 (VSV-G envelope) and pCMVΔ8.91 
(gag-pol plasmid) with the corresponding viral construct, using polyeth-
ylenimine (Sigma-Aldrich), with sodium butyrate stimulation for the first 
24 hours (Sigma Aldrich). Virus supernatant was collected 48–72 hours 
after transfection, and viral particles were concentrated by ultracentrifu-
gation or tangential flow.49 Evaluation of LV EFS ADA in the NSG mice 
was performed with vector produced in two batches produced under 
Good Manufacturing Practice at the Indiana University Vector Production 
Facility.50 The LV vector DNA titer was determined on murine SC-1 fibro-
blasts and human HT29 colon carcinoma cells which were harvested at 72 
hours after transduction and DNA was extracted with DNeasy Blood and 
Tissue kit (Qiagen, UK) following the manufacturer’s instructions. qPCRs 
were performed with primers and probe to detect the HIV psi region 
specific for the packaging region of LVs (sense primer 5′-acctgaaagc-
gaaagggaaac-3′, antisense primer 5′-cgcacccatctctctccttct-3′, and probe 
FAM-agctctctcgacgcaggactcggc-TAMRA).
gRV. The gRVSFada/W and gRV SF91 GFP vectors were packaged 
in HEK293T cells by triple transfection of the packaging plasmids pEco 
(murine ecotropic envelope; Clontech, Europe) and M13 (MuLV gag/
pol expression plasmid, kind gift from Professor Christopher Baum) 
with corresponding construct using Calcium Phosphate Transfection Kit 
(CAPHOS, Sigma) under manufacturer’s instructions. Supernatants were 
collected 48–72 hours after transfection and filtered through a 0.45 μm 
filter. The vector titer was determined on murine SC-1 fibroblasts by spin-
oculation with serial dilutions of supernatant for 40 minutes at 1,000 xg, 4 
°C in the presence of 8 μg/ml polybrene. Viral transduced cells were har-
vested after 72 hours and DNA extracted with DNeasy Blood and Tissue kit 
(Qiagen) following the manufacturer’s instructions. qPCR were performed 
with primers and probe to detect a common region in wPRE fragment 
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in the gRV GFP vectors28 or viral integrations, Titin for murine cells or 
b-actin for human cells as DNA-loading control. The gRV SF91 GFP vector 
was also packaged from a stable clone of the GP+E86 ecotropic packag-
ing cell line as a positive control for the in vitro insertional mutagenesis 
(IVIM) assay at UCLA. Titer was determined on HT29 cells and DNA was 
extracted with DNeasy Blood and Tissue kit (Qiagen) following the manu-
facturer’s instructions. qPCR were performed with primers and probe to 
detect GFP (sense primer is 5′-ctgctgcccgacaacca-3′, antisense primer is 
5′-gaactccagcaggaccatgtg-3′, and probe 5′-FAM - ccctgagcaaagaccccaac-
gaga-Tamra-3′). The gRV-MND-ADA vector supernatant was produced 
from a stable clone of the PG13 GALV-packaging line as described.12
All experiments were performed with thawed vector stocks of known 
titers (LV: 0.6–10 × 109 transducing units (TU)/ml; gRVSFada/W and gRV 
SF91 GFP: 1–10 × 106 TU/ml); gRV MND-ADA: 1.8 × 105 TU/ml).
Enrichment, transduction, and transplantation of murine ADA−/− BM 
Lin- HSCs
Enrichment and transduction of ADA−/− HSC. The BM cells were har-
vested by flushing tibias, femora, and pelvis of age-matched male donor 
ADA+/+ or ADA−/− mice. BM lineage negative (Lin-) cells were enriched 
with the BDIMag Mouse Hematopoietic Progenitor Cell Enrichment Set 
(BD Biosciences, San Jose, CA) and preactivated in Stemspan serum-free 
expansion medium (SFEM) (StemCell Technologies, UK) in the presence 
of 100 ng/ml of murine stem cell factor, human Flt3 ligand (Flt3-L), murine 
thrombopoietin (mTPO), and 20 ng/ml of murine interleukin-3 (IL-3). 
After 24-hour preactivation, the LV EFS ADA or LV EFS GFP vectors were 
directly added to cells at a MOI of 20 and incubated for 16–24 hours. For 
SFada/W gRV vector, the cells were preactivated for 72 hours and then 
underwent a two-round transduction protocol with a 6-hour gap. In each 
round, viral particles corresponding to a MOI of 20 were spinoculated for 
40 minutes at 1,000 g, 4 °C onto a retronectin-coated plate. The cells were 
added into virus-coated plates after removal of supernatant. After 24 hours 
after transduction, all cells were injected via the tail vein into 4–12 weeks 
old sublethally irradiated (5 Gy, split dose) female ADA−/− recipients at a 
dose of 5 × 105 cells/mouse. In ADA−/− WT group, isolated ADA+/+ BM 
Lin- cells were injected instead. All transplants were maintained on ERT 
with weekly i.p. injection of PEG-ADA at 1,000 units/kg for 4 weeks post-
transplantation. A group of age-matched ADA−/− mice under continuous 
PEG-ADA injection were used as a positive control. The negative control 
group of untreated ADA−/− mice were euthanized at day 18-20 after birth.
Isolation, transduction, and transplantation of human HSC
Isolation. Human CD34+ cells (HSC) were isolated from anonymous waste 
normal human cord blood and bone marrow, which has been deemed 
exempt from IRB review as not constituting human subjects research, and 
from ADA-deficient SCID bone marrow, under approved UCLA IRB #10-
001399 with informed consent provided by parents of the subjects. Normal 
human adult bone marrow samples (100 ml/donor) were also purchased 
from AllCells, LLC (Emeryville, CA). Human CD34+ cell isolation was 
performed as described.51 Briefly, human cord blood or human bone mar-
row was diluted 1:2 with Dulbecco’s phosphate-buffered saline and distrib-
uted into 50 ml conical tubes containing 15 ml of Ficoll-Paque PLUS (GE 
HealthCare Life Sciences, Piscataway, NJ) and centrifuged (no brake) at 
400 xg for 30 minutes at room temperature. The mononuclear cells (the 
buffy coat) were harvested and CD34+ cells were isolated by immuno-
magnetic separation with the Miltenyi MACS CD34+ Cell Isolation Kit 
(Miltenyi Biotech, Auburn, CA). Cells were counted and either transduced 
as freshly isolated CD34+ cells or cryopreserved (freezing medium: 90% 
serum and 10% DMSO) and then transduced after thawing.
Transduction. Human CD34+ cells (100,000 or 500,000 cell/ml), were 
plated on Retronectin coated six-well plates (20 µg/ml; Takara/Clontech, 
Mountain View, CA) and prestimulated for 24 hours in X-Vivo 15 serum-
free medium (Biowhittaker/Lonza, Walkersville, MD) supplemented with 
L-glutamine (2 mmol/l), human TPO (100 ng/ml), human stem cell factor 
(300 ng/ml), human Flt3 ligand (Flt3-L; 300 ng/ml), and with or without 
IL-3 (20 ng/ml) (all cytokines from BioLegend, San Diego, CA). The cells 
were transduced with the EFS-ADA LV at a concentration of 3.0 × 107 TU/
ml (except where indicated otherwise) for 18–20 hours at 37 °C with 5% 
CO2. gRV transductions were done following 2 days of prestimulation, as 
above, by adding unconcentrated gRV-MND-ADA vector supernatant to 
cells daily × 3 days.12
Transplantation. Irradiated (150 cGy) neonatal NSG mice were 
transplanted with 50,000 to 100,000 transduced (LV EFS ADA) or non-
transduced (mock) human CD34+ cells by intravenous injection into the 
superficial temporal (facial) vein between postnatal day 1 and 3. The mice 
were euthanized 4 months after transplant, and the thymus, spleen, and 
bone marrow were harvested and analyzed for the presence of human 
cells (engraftment) and vector (VCN and expression). Bone marrow cells 
were isolated from each primary recipient, red blood cells were lysed, and 
1 × 10e7 nucleated cells were serially transplanted into a conditioned sec-
ondary recipient (250cGy).
Analysis in vitro of transduced human HSC
Myeloid culture. Immediately following the transduction period, the 
LV-transduced and mock-transduced cultures were maintained in Iscove’s 
modified Dulbecco’s medium supplemented with 20% fetal calf serum 
(Omega Scientific, Tarzana, CA), 0.5% human serum albumin (AlbuRx 
25; CSL Behring LLC, Kankakee, IL), L-glutamine (2 mmol/l), penicillin/
streptomycin (100 U/ml), human IL-3 (5 ng/ml), IL-6 (10 ng/ml), and stem 
cell factor (25 ng/ml) (all cytokines from BioLegend). On day 7, one half 
of the medium was exchanged for fresh medium with freshly diluted cyto-
kines. On day 14 of posttransduction culture, 1 × 106 cells were harvested 
for DNA extraction and 0.5 × 106 cells were harvested for ADA enzyme 
activity assay. DNA was purified using the DNAeasy kit (Qiagen, Valencia, 
CA) and ADA enzyme activity was determined with the ADA enzyme 
assay by Diazyme (San Diego, CA).
Colony assays. Samples of the transduced CD34+ cells were also 
plated for progenitor assays (CFU) (two to three dilutions in duplicate) in 
semisolid methylcellulose medium supplemented with cytokines (Stem 
Cell Technologies, Vancouver, BC, Canada). Between days 11 and 14, 
colonies were counted and characterized by progenitor type. Single colo-
nies were aspirated from the methylcellulose and placed into a microcen-
trifuge tube containing 1 ml of Dulbecco’s phosphate-buffered saline for 
1 hour at 37 °C. The tubes were centrifuged for 10 minutes at 400 xg and 
cell pellets stored at −20 °C for later DNA extraction and VCN analysis. 
Colony DNA was purified with a single phenol/chloroform extraction, 
precipitated in the presence of glycogen (20 mg/ml, Roche Diagnostics, 
Mannheim, Germany; Invitrogen, Carlsbad, CA) and resuspended in 25 
µl of Tris-EDTA (pH 7.4). To determine CFU VCN, 5 µl of the extracted 
DNA were analyzed by Multiplex qPCR using primers/probe for the 
human ADA cDNA and the human SDC4 gene (to normalize for DNA 
concentration) and compared to the EFS-ADA copy number standard 
described above.
Flow cytometry analysis for immunophenotype and engraftment
ADA mice. The percentage of T cells (CD3+, CD4+, and CD8+), B cells 
(B220+), myeloid cells (GR-1+), and natural killer (NK1.1+) cells were ana-
lyzed in the PB, thymus, spleen, or bone marrow of ADA mice. For flow 
cytometry, 2 × 105 cells from red cell lysed PB, lymphoid organs, or bone 
marrow were preincubated for 15 minutes at room temperature with murine 
serum followed by staining for 30 minutes at 4 °C with anti-mouse antibod-
ies all from BD Pharmingen including: PE-CD3, PE Cy7-CD4, APC-CD8a, 
APC-B220, APC-GR-1, and APC-NK1.1. After washing, cells were analyzed 
using CyAn ADP Analyzer (Beckman Coulter) and Summit software.
NSG mice. In transplanted NSG mice, the level of engraftment and the 
immunophenotype of human cells were determined by flow cytometry 
(FACS) immunostaining with anti-human antibodies from BD Biosciences 
and flow cytometry on a BD LSRII instrument with DIVA (BD Biosciences) 
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Software. Percent engraftment was determined on bone marrow cell sus-
pensions (flushed from femur and tibia bones) immunostained with anti-
human CD45 (PerCp or APC). The percentage of engrafted human cell 
lineages was determined on tissue cell suspensions immunostained as fol-
lows: thymus-anti-human CD4-PE, anti-human CD8-APC; spleen-anti-
human CD3-PE, anti-human CD19-APC; and bone marrow anti-human 
CD11b-APC, anti-human gran-1-PE.
Quantification by qPCR for VCN and donor cell engraftment. All 
amplification reactions were performed in the 7,500 Fast Real-Time PCR 
System (Applied Biosystems/Life Technologies (LT) UK and USA) under 
default conditions and analyzed using Manufacturer’s software.
ADA mice. Genomic DNA was extracted from murine tissues and PB 
by DNeasy Blood & Tissue Kit (Qiagen). VCN in total cells from differ-
ent organs was detected by qPCR using primers amplifying sequences in 
wPRE or Titin.28 Known copies of wPRE from LV-transduced MEL cells 
serially diluted into irrelevant genomic DNA was used to set up a standard 
curve. The frequency of male donor cells was determined by qPCR for the 
Y chromosome using primers described previously.34 These data were cal-
culated using a standard curve of serially diluted male cells into female 
cells from ADA mice.
NSG mice. Genomic DNA was extracted from murine spleen and bone 
marrow with DNeasy Blood & Tissue Kit (Qiagen). From smaller thymic 
tissue samples (0.5–1 × 105 cells), DNA was extracted with phenol chloro-
form extraction as described previously.12 The human ADA gene in both 
gRV (not codon optimized) and LV vectors (codon optimized) was ampli-
fied using primers and probe that span exon 6 and 7 of the human ADA 
gene (sense primer 5′-ggtccatcctgtgctgcat-3′, anti-sense primer 5′-cggtct-
gctgctggtacttctt-3′, and probe 5′-FAM-ccagcccaactggtcccccaag-tamra-3′). 
VCN was normalized by qPCR of the human syndecan 4 gene (SDC4) 
(sense primer 5′-cagggtctgggagccaagt-3′, anti-sense primer 5′-gcacagt-
gctggacattgaca-3′, and probe 5-HEX-cccaccgaacccaagaaactagaggagaat-
Iowa Black FQ. DNA extracted from a cellular clone containing four copies 
of integrated LV EFS ADA vector was serially diluted into equally concen-
trated DNA from nontransduced cells to make the standard curve used to 
quantify the VCN per cell.
ADA and SAHH activity assay
ADA mice. ADA activity assay was performed with cell lysates from 
transplanted ADA−/− and controls prepared in 200–500 μl of H2O per 
sample. 12.5 μl of the lysate was incubated with the reaction mix con-
taining 50 μl of phosphate-buffered saline (Invitrogen/Life technologies), 
37.5 μl of 10 mmol/l adenosine (Sigma-Aldrich) for 0 or 20 minutes in 37 
°C water bath. Then, the reaction was stopped by 12.5 μl of 40% trichlo-
roacetic acid (Sigma-Aldrich). The precipitations were spun down, and 
trichloroacetic acid in the supernatant was extracted by H2O-saturated 
diethyl ether.
ADA mice. For SAHH activity assay, 100 μl of master mix (50 μl of 
62.5 mmol/l KH2PO4, 5 μl of 20 mmol/l DTT, 10 μl of 10 mmol/l EDTA, 
20 μl of 37.5 mmol/l homocysteine, and 15 μl of H2O) was added into each 
tube with 10 μl of 150 μmol/l deoxycoformycin (Pentostatin; TOCRIS 
Bioscience, UK) and 25 μl of lysate. The tubes were preincubated in a 37 °C 
water bath for 5 minutes. To start the reaction, 10 μl of 6.5 mmol/l adenos-
ine was added into the mixture and incubated for 0 or 60 minutes at 37 
°C until stopped by adding in 25 μl of 40% trichloroacetic acid. The pre-
cipitations were spun down and trichloroacetic acid in the supernatant was 
extracted by H2O-saturated diethyl ether. The level of substrates in ADA 
or SAHH activity assays was measured on anion-pair HPLC Waters 2795 
system with PDA detection (Waters, Milford, MA). The final ADA activity 
was normalized with protein concentration or hemoglobin concentration.
NSG mice. ADA enzyme activity was measured in human cells iso-
lated from total tissue cell suspensions of spleen and bone marrow using 
the anti-human CD45 Miltenyi MACs Cell Separation System (Miltenyi 
Biotech, Auburn, CA). Mice transplanted with mock-transduced cells were 
also used to determine a baseline of ADA activity in the engrafted human 
cells, as the CD34+ cells from ADA replete cord blood or bone marrow will 
have background ADA expression. A colorimetric ADA enzyme assay kit 
(Diazyme Laboratories, Poway, CA) was used to determine the amount of 
ADA enzyme activity in the primary human CD34+ cells from in vitro cul-
ture and from human cells isolated from NSG mice. Cells (0.5 × 106 cells) 
were centrifuged at 400 × g for 5 minutes and a dry pellet was frozen at −80 
°C for batch assays. The kit uses a calibrator that is serially diluted to make a 
standard curve for quantification. The catalytic conversion of adenosine by 
ADA enzyme is ultimately read-out by the conversion of hypoxanthine to 
uric acid and hydrogen peroxide that reacts with N-Ethyl-N-(2-hydroxy-
3-sulfopropyl)-3-methylaniline and 4-aminoantipyrine in the presence of 
peroxidase to generate quinone dye, which is detected spectrophotometri-
cally at 550 nm.
Western blot. The cell lysate was prepared with 1 × 106 cells in RIPA lysis 
buffer by standard method and subjected to sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis. The proteins were transferred to nitrocel-
lulose membrane (Sigma-Aldrich). Anti-ADA antibody was a kind gift 
from Dr. M. Hershfield (Duke University, Durham, NC). Anti-GAPDH 
monoclonal antibody was obtained from Santa Cruz Biotechnology (Santa 
Cruz, Germany).
Histological analysis. Tissues and organs of ADA mice including lung, liver, 
heart, and kidney were harvested and examined histologically. Tissues and 
organs were rinsed in phosphate-buffered saline and then fixed in 10% 
formalin for more than 24 hours at 4 °C. Then, tissues were dehydrated, 
cleared, and embedded in paraffin following routine procedures. Sections 
of 4 µm in size were cut and stained with hematoxylin and eosin and 
mounted using standard protocols for histopathological analysis under an 
optical microscope (Olympus BX50).
IVIM-WST1 assay. In vitro immortalization assay was adopted from 
Modlich et al.25 Briefly, BM Lin- cells of C57BL6 mice were isolated with 
the BDIMag Mouse Hematopoietic Progenitor Cell Enrichment Set (BD 
Biosciences, 558451) and preactivated in Stemspan serum-free expan-
sion medium (StemCell Technologies) containing 50 ng/ml murine stem 
cell factor, 100 ng/ml hFlt-3 ligand, 100 ng/ml hIL-11, and 10 ng/ml mIL-3 
(PeproTech, UK) at a density of 5 × 105 cells/ml. 1 × 105 cells were trans-
duced on day 4 and 5 at an MOI of 20 for each viral vector. LVs were 
directly added to cells. gRVs were preloaded on retronectin-coated plate 
(TaKaRa, Japan) by spinoculation for 40 minutes at 4 °C and then incu-
bated with cells for 16–24 hours.
After two-round transductions, cells were expanded as bulk 
populations for 2 weeks in Iscove’s modified Dulbecco’s medium 
containing the same cytokine cocktail as above with 10% fetal calf serum. 
DNA samples were taken at day 9 for vector copy analyses by qPCR. 
Two weeks later, cells were plated into 96-well plates at a density of 100 
cells per well and incubated at 37 °C for another 14 days. Subsequently, 
half of cells from each well were incubated with 10 μl of WST-1 (Roche, 
Europe) for 4 hours at 37 °C. The absorbance was measured at 450 nm 
in a FLUOstar Optima luminometer (BMG Labtech, Ortenberg, 
Germany). The highest absorbance from mock-transduced clones was 
set as the baseline above which all clones were counted as positive ones. 
The frequency of replating cells was calculated using L-Calc software 
(Stem Cell Technologies) and normalized with VCN. Selected clones 
were expanded for further characterization.
Statistical analysis. Descriptive statistics of continuous outcome variables, 
such as the means and standard error by experimental groups, are pre-
sented in figures and data tables. For continuous outcome measurements, 
group differences were assessed by unpaired t-test (for two experimental 
groups) or one-way/two-way analysis of variance with interaction (for 
more than two groups)52 followed by pairwise comparisons. Linear mixed 
models53 were used for dose-dependent analysis. Concentration and MOI 
were modeled as the fixed effects, while experiments or donors were 
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modeled as random effects to account for the random variations in the 
data. Wilcoxon rank sum test was used for IVIM assay analysis. For all 
statistical investigations, tests for significance were two-tailed unless oth-
erwise specified. A P value less than the 0.05 significance level was consid-
ered to be statistically significant (*). All statistical analyses were carried 
out using SAS version 9.3.54
SUPPLEMENTARY MATERIAL
Figure S1. Transduction and expression by EFS-ADA in human 
CD34+ cells.
Figure S2. The LV EFS ADA vector shows significantly decreased 
transformation potential than the SFada/W vector.
Table S1. In vitro immortalization assay cell replating frequency.
ACKNOWLEDGMENTS
In the United Kingdom, studies were funded by grants from the 
Medical Research Council (L.Z and C.M-E.) and the NIHR Biomedical 
Research Centre at Great Ormond Street Hospital (C.M-E. and A.J.T). 
The authors acknowledge the support of GOSHCC (H.B.G), Wellcome 
Trust (A.J.T and M.P.B.) and the European Commission’s 7th Framework 
Program Contract 261387 (CELL-PID). In the United States, studies 
were supported by research grants from the National Institutes of 
Health (2P01 HL073104, 1R01 A1074043, and U01 AI100801), and 
by the University of California, Los Angeles Jonsson Comprehensive 
Cancer Center and the Eli and Edythe Broad Center for Regenerative 
Medicine and Stem Cell Research. Vector production in the Indiana 
University Vector Production Facility was supported by the NHLBI 
Gene Therapy Resource Program (HHSN2682012000051). The Flow 
Cytometry Core and High-Throughput Sequencing Core of the Broad 
Stem Cell Research Center were essential to performing these stud-
ies. Ute Modlich and Chris Baum, Hannover Medical School, Germany 
generously provided reagents, protocols, and advice for establishing 
the in vitro immortalization assay. Finally, we would like to thank the 
parents of the ADA SCID subjects who gave consent for provision of 
bone marrow aspirates for these studies.
REFERENCES
1. Hershfield, MS (1998). Adenosine deaminase deficiency: clinical expression, molecular 
basis, and therapy. Semin Hematol 35: 291–298.
2. Apasov, SG, Blackburn, MR, Kellems, RE, Smith, PT and Sitkovsky, MV (2001). 
Adenosine deaminase deficiency increases thymic apoptosis and causes defective T 
cell receptor signaling. J Clin Invest 108: 131–141.
3. Albuquerque, W and Gaspar, HB (2004). Bilateral sensorineural deafness in adenosine 
deaminase-deficient severe combined immunodeficiency. J Pediatr 144: 278–280.
4. Ratech, H, Greco, MA, Gallo, G, Rimoin, DL, Kamino, H and Hirschhorn, R 
(1985). Pathologic findings in adenosine deaminase-deficient severe combined 
immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J 
Pathol 120: 157–169.
5. Blackburn, MR, Datta, SK and Kellems, RE (1998). Adenosine deaminase-deficient 
mice generated using a two-stage genetic engineering strategy exhibit a combined 
immunodeficiency. J Biol Chem 273: 5093–5100.
6. Booth, C, Hershfield, M, Notarangelo, L, Buckley, R, Hoenig, M, Mahlaoui, N et al. 
(2007). Management options for adenosine deaminase deficiency; proceedings 
of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 123: 
139–147.
7. Gaspar, HB, Aiuti, A, Porta, F, Candotti, F, Hershfield, MS and Notarangelo, LD (2009). 
How I treat ADA deficiency. Blood 114: 3524–3532.
8. Blaese, RM, Culver, KW, Miller, AD, Carter, CS, Fleisher, T, Clerici, M et al. (1995). 
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. 
Science 270: 475–480.
9. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. (2002). Correction of 
ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. 
Science 296: 2410–2413.
10. Aiuti, A, Vai, S, Mortellaro, A, Casorati, G, Ficara, F, Andolfi, G et al. (2002). Immune 
reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme 
replacement. Nat Med 8: 423–425.
11. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. 
(2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. 
N Engl J Med 360: 447–458.
12. Candotti, F, Shaw, KL, Muul, L, Carbonaro, D, Sokolic, R, Choi, C et al. (2012). 
Gene therapy for adenosine deaminase-deficient severe combined immune 
deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 
120: 3635–3646.
13. Gaspar, HB, Cooray, S, Gilmour, KC, Parsley, KL, Zhang, F, Adams, S et al. (2011). 
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe 
combined immunodeficiency leads to long-term immunological recovery and 
metabolic correction. Sci Transl Med 3: 97ra80.
14. Boztug, K, Schmidt, M, Schwarzer, A, Banerjee, PP, Díez, IA, Dewey, RA et al. 
(2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363: 
1918–1927.
15. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. 
(2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of 
SCID-X1. J Clin Invest 118: 3132–3142.
16. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, 
Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients 
after gene therapy for SCID-X1. Science 302: 415–419.
17. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, 
H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations 
causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 
3143–3150.
18. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). 
Correction of X-linked chronic granulomatous disease by gene therapy, augmented 
by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401–409.
19. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). 
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 
activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198–204.
20. Aiuti, A, Cassani, B, Andolfi, G, Mirolo, M, Biasco, L, Recchia, A et al. (2007). 
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID 
patients treated with stem cell gene therapy. J Clin Invest 117: 2233–2240.
21. Dull, T, Zufferey, R, Kelly, M, Mandel, RJ, Nguyen, M, Trono, D et al. (1998). 
A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 
8463–8471.
22. Miyoshi, H, Blömer, U, Takahashi, M, Gage, FH and Verma, IM (1998). Development 
of a self-inactivating lentivirus vector. J Virol 72: 8150–8157.
23. Naldini, L, Blömer, U, Gallay, P, Ory, D, Mulligan, R, Gage, FH et al. (1996). In vivo 
gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 
272: 263–267.
24. Modlich, U, Navarro, S, Zychlinski, D, Maetzig, T, Knoess, S, Brugman, MH et al. 
(2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral 
and gammaretroviral vectors. Mol Ther 17: 1919–1928.
25. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knöss, S, Schambach, A et al. (2006). 
Cell-culture assays reveal the importance of retroviral vector design for insertional 
genotoxicity. Blood 108: 2545–2553.
26. Cartier, N, Hacein-Bey-Abina, S, Von Kalle, C, Bougnères, P, Fischer, A, Cavazzana-
Calvo, M et al. (2010). Gene therapy of x-linked adrenoleukodystrophy using 
hematopoietic stem cells and a lentiviral vector. Bull Acad Natl Med 194: 255–64; 
discussion 264.
27. Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). 
Transfusion independence and HMGA2 activation after gene therapy of human  
ß-thalassaemia. Nature 467: 318–322.
28. Montiel-Equihua, CA, Zhang L, Knight S, Saadeh H, Scholz S, Carmo M et al. 
(2012). The beta-globin locus control region in combination with the EF1alpha short 
promoter allows enhanced lentiviral vector-mediated erythroid gene expression with 
conserved multilineage activity. Mol Ther 20: 1400–1409.
29. Corrigan-Curay, J, Cohen-Haguenauer, O, O’Reilly, M, Ross, SR, Fan, H, Rosenberg, 
N et al. (2012). Challenges in vector and trial design using retroviral vectors for 
long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther 20: 
1084–1094.
30. Carbonaro, DA, Jin, X, Wang, X, Yu, XJ, Rozengurt, N, Kaufman, ML et al. (2012). 
Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-
replacement therapy and cytoreduction. Blood 120: 3677–3687.
31. Thompson, LF, Van de Wiele, CJ, Laurent, AB, Hooker, SW, Vaughn, JG, Jiang, H et al. 
(2000). Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine 
deaminase-deficient fetal thymic organ cultures. J Clin Invest 106: 1149–1157.
32. Zhang, F, Frost, AR, Blundell, MP, Bales, O, Antoniou, MN and Thrasher, AJ (2010). 
A ubiquitous chromatin opening element (UCOE) confers resistance to DNA 
methylation-mediated silencing of lentiviral vectors. Mol Ther 18: 1640–1649.
33. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. 
(2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. 
Mol Ther 16: 718–725.
34. Mortellaro, A, Hernandez, RJ, Guerrini, MM, Carlucci, F, Tabucchi, A, Ponzoni, M et 
al. (2006). Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase 
(ADA)-deficient mice and corrects their immune and metabolic defects. Blood 108: 
2979–2988.
35. Booth, C, Algar, VE, Xu-Bayford, J, Fairbanks, L, Owens, C and Gaspar, HB (2012). 
Non-infectious lung disease in patients with adenosine deaminase deficient severe 
combined immunodeficiency. J Clin Immunol 32: 449–453.
36. Ficara, F, Superchi, DB, Hernández, RJ, Mocchetti, C, Carballido-Perrig, N, Andolfi, G 
et al. (2004). IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM 
CD34+ cells while maintaining in vivo lymphoid potential. Mol Ther 10: 1096–1108.
37. Uchida, N, Hsieh, MM, Hayakawa, J, Madison, C, Washington, KN and Tisdale, JF 
(2011). Optimal conditions for lentiviral transduction of engrafting human CD34+ 
cells. Gene Ther 18: 1078–1086.
38. Kohn, LA, Hao, QL, Sasidharan, R, Parekh, C, Ge, S, Zhu, Y et al. (2012). Lymphoid 
priming in human bone marrow begins before expression of CD10 with upregulation 
of L-selectin. Nat Immunol 13: 963–971.
39. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. 
(2009). The genotoxic potential of retroviral vectors is strongly modulated by vector 
design and integration site selection in a mouse model of HSC gene therapy. J Clin 
Invest 119: 964–975.
40. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human 
genome are favored targets for MLV integration. Science 300: 1749–1751.
41. Beard, BC, Dickerson, D, Beebe, K, Gooch, C, Fletcher, J, Okbinoglu, T et al. (2007). 
Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector 
integration sites in primate repopulating cells. Mol Ther 15: 1356–1365.
42. Beard, BC, Keyser, KA, Trobridge, GD, Peterson, LJ, Miller, DG, Jacobs, M et al. 
(2007). Unique integration profiles in a canine model of long-term repopulating cells 
Molecular Therapy vol. 22 no. 3 mar. 2014 621
© The American Society of Gene & Cell Therapy
Lentiviral Vector Correction of ADA Deficiency
transduced with gammaretrovirus, lentivirus, or foamy virus. Hum Gene Ther 18: 
423–434.
43. Aiuti, A, Cossu, G, de Felipe, P, Galli, MC, Narayanan, G, Renner, M et al. (2013). 
The committee for advanced therapies’ of the European Medicines Agency reflection 
paper on management of clinical risks deriving from insertional mutagenesis. Hum 
Gene Ther Clin Dev 24: 47–54.
44. Biffi, A, Montini, E, Lorioli, L, Cesani, M, Fumagalli, F, Plati, T et al. (2013). Lentiviral 
hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 
341: 1233158.
45. Shultz, LD, Lyons, BL, Burzenski, LM, Gott, B, Chen, X, Chaleff, S et al. (2005). 
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma 
null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 
6477–6489.
46. Gaspar, HB, Bjorkegren, E, Parsley, K, Gilmour, KC, King, D, Sinclair, J et al. (2006). 
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following 
cessation of PEG-ADA and use of mild preconditioning. Mol Ther 14: 505–513.
47. Demaison, C, Parsley, K, Brouns, G, Scherr, M, Battmer, K, Kinnon, C et al. (2002). 
High-level transduction and gene expression in hematopoietic repopulating cells 
using a human immunodeficiency [correction of imunodeficiency] virus type 1-based 
lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene 
Ther 13: 803–813.
48. Schambach, A, Wodrich, H, Hildinger, M, Bohne, J, Kräusslich, HG 
and Baum, C  (2000). Context dependence of different modules for 
posttranscriptional enhancement of gene expression from retroviral vectors. Mol 
Ther 2: 435–445.
49. Cooper, AR, Patel, S, Senadheera, S, Plath, K, Kohn, DB and Hollis, RP (2011). Highly 
efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. 
J Virol Methods 177: 1–9.
50. Leath, A and Cornetta, K (2012). Developing novel lentiviral vectors into clinical 
products. Meth Enzymol 507: 89–108.
51. Nightingale, SJ, Hollis, RP, Pepper, KA, Petersen, D, Yu, XJ, Yang, C et al. (2006). 
Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 13: 
1121–1132.
52. Tukey, J (1957). Variances of variance components: II. Unbalanced single 
classifications. The Annals of Mathematical Statistics 28: 43–56.
53. West, BT, Welch, KB and Galecki, AT (2007). Linear Mixed Models: A Practical Guide to 
Using Statistical Software. Chapman & Hall/CRC: New York.
54. SAS Institute (2012). SAS/STAT user’s guide, Version 9.3. 9.3 ed. SAS Institute: Cary, NC.
622 www.moleculartherapy.org vol. 22 no. 3 mar. 2014
